HSP-CAR30

BIOLOGICAL2 trials

Sponsors

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Conditions

Hodgkin Lymphoma, AdultRefractary or relapse Hodgkin T CD30+ lymphomaRefractary or relapse non-Hodgkin T CD30+ lymphoma.T Cell Lymphoma

Phase 1

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauHodgkin Lymphoma, Adult, T Cell Lymphoma

Start: 2020-09-29End: 2023-12-30Target: 30Updated: 2020-12-04

Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.

Not yet recruitingCTIS2024-515624-36-00

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant PauRefractary or relapse Hodgkin T CD30+ lymphoma, Refractary or relapse non-Hodgkin T CD30+ lymphoma.

Target: 40Updated: 2025-08-29

Related Papers

HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma

Blood2025-01-224 citations

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30+ T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Blood2024-11-051 citations

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30+ T-Cell Lymphoma: Clinical and Biological Studies

Blood2022-11-1511 citations

S257: A PHASE 1, FIRST-IN-HUMAN, DOSE-ESCALATION CLINICAL TRIAL OF MEMORY-ENRICHED CD30-CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AND CD30+ T-CELL LYMPHOMA

HemaSphere2022-06-012 citations